SK6602000A3 - Porous hydroxyapatite particles as carriers for drug substances - Google Patents

Porous hydroxyapatite particles as carriers for drug substances Download PDF

Info

Publication number: SK6602000A3
Authority: SK; Slovakia
Prior art keywords: oily; sticky; active substance; pharmaceutical active; substance
Prior art date: 1997-11-28

Application number

SK660-2000A

Other languages

English (en)

Slovak (sk)

Inventor

Christer Karlsson

Per Johan Lundberg

Adam Rosinski

Malin Soderbom

Original Assignee

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-11-28

Filing date

1998-11-19

Publication date

2001-01-18

1998-11-19 Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

2001-01-18 Publication of SK6602000A3 publication Critical patent/SK6602000A3/sk

Links

229910052588 hydroxylapatite Inorganic materials 0.000 title claims description 21
XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 title claims description 17
239000002245 particle Substances 0.000 title description 27
239000000969 carrier Substances 0.000 title 1
229940088679 drug related substance Drugs 0.000 title 1
239000000126 substance Substances 0.000 claims abstract description 25
239000013543 active substance Substances 0.000 claims abstract description 18
238000012377 drug delivery Methods 0.000 claims abstract description 10
239000010954 inorganic particle Substances 0.000 claims abstract description 8
239000007787 solid Substances 0.000 claims abstract description 6
ZMHOBBKJBYLXFR-BPNWFJGMSA-N 4-[(2r)-3-[ethyl(3-propylsulfinylpropyl)amino]-2-hydroxypropoxy]benzonitrile Chemical compound CCCS(=O)CCCN(CC)C[C@@H](O)COC1=CC=C(C#N)C=C1 ZMHOBBKJBYLXFR-BPNWFJGMSA-N 0.000 claims description 12
229950003699 almokalant Drugs 0.000 claims description 12
239000000919 ceramic Substances 0.000 claims description 11
239000003814 drug Substances 0.000 claims description 10
239000000203 mixture Substances 0.000 claims description 10
RZTAMFZIAATZDJ-HNNXBMFYSA-N 5-o-ethyl 3-o-methyl (4s)-4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical group CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-HNNXBMFYSA-N 0.000 claims description 9
229960003580 felodipine Drugs 0.000 claims description 9
DKWNMCUOEDMMIN-PKOBYXMFSA-N melagatran Chemical group C1=CC(C(=N)N)=CC=C1CNC(=O)[C@H]1N(C(=O)[C@H](NCC(O)=O)C2CCCCC2)CC1 DKWNMCUOEDMMIN-PKOBYXMFSA-N 0.000 claims description 7
229960002137 melagatran Drugs 0.000 claims description 7
229940079593 drug Drugs 0.000 claims description 5
238000004519 manufacturing process Methods 0.000 claims description 3
108090000190 Thrombin Proteins 0.000 claims 1
239000004480 active ingredient Substances 0.000 claims 1
230000002401 inhibitory effect Effects 0.000 claims 1
108090000765 processed proteins & peptides Proteins 0.000 claims 1
229960004072 thrombin Drugs 0.000 claims 1
238000000034 method Methods 0.000 abstract description 5
238000004090 dissolution Methods 0.000 description 10
230000001050 lubricating effect Effects 0.000 description 10
239000012738 dissolution medium Substances 0.000 description 9
239000003921 oil Substances 0.000 description 9
235000019198 oils Nutrition 0.000 description 9
238000003756 stirring Methods 0.000 description 7
239000002552 dosage form Substances 0.000 description 5
239000000463 material Substances 0.000 description 5
241000499489 Castor canadensis Species 0.000 description 4
235000011779 Menyanthes trifoliata Nutrition 0.000 description 4
238000010521 absorption reaction Methods 0.000 description 4
238000009472 formulation Methods 0.000 description 4
239000002609 medium Substances 0.000 description 4
239000008363 phosphate buffer Substances 0.000 description 4
239000002904 solvent Substances 0.000 description 4
238000000870 ultraviolet spectroscopy Methods 0.000 description 4
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
239000002775 capsule Substances 0.000 description 3
239000007903 gelatin capsule Substances 0.000 description 3
238000012360 testing method Methods 0.000 description 3
229920002690 Polyoxyl 40 HydrogenatedCastorOil Polymers 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
235000014113 dietary fatty acids Nutrition 0.000 description 2
238000009826 distribution Methods 0.000 description 2
239000003623 enhancer Substances 0.000 description 2
239000000194 fatty acid Substances 0.000 description 2
229930195729 fatty acid Natural products 0.000 description 2
150000004665 fatty acids Chemical class 0.000 description 2
238000005470 impregnation Methods 0.000 description 2
238000002156 mixing Methods 0.000 description 2
239000008389 polyethoxylated castor oil Substances 0.000 description 2
BNZPFJBUHRBLNB-UHFFFAOYSA-N 1-oxido-1,2,4-benzotriazin-1-ium Chemical compound C1=CC=C2[N+]([O-])=NC=NC2=C1 BNZPFJBUHRBLNB-UHFFFAOYSA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
CDPROXZBMHOBTQ-SJORKVTESA-N 2-[[(2r)-3-cyclohexyl-1-[(2s)-2-[3-(diaminomethylideneamino)propylcarbamoyl]piperidin-1-yl]-1-oxopropan-2-yl]amino]acetic acid Chemical compound NC(N)=NCCCNC(=O)[C@@H]1CCCCN1C(=O)[C@H](NCC(O)=O)CC1CCCCC1 CDPROXZBMHOBTQ-SJORKVTESA-N 0.000 description 1
RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
229930105110 Cyclosporin A Natural products 0.000 description 1
108010036949 Cyclosporine Proteins 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
244000046052 Phaseolus vulgaris Species 0.000 description 1
229910004298 SiO 2 Inorganic materials 0.000 description 1
FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
238000000149 argon plasma sintering Methods 0.000 description 1
229940088623 biologically active substance Drugs 0.000 description 1
229960001265 ciclosporin Drugs 0.000 description 1
239000003240 coconut oil Substances 0.000 description 1
235000019864 coconut oil Nutrition 0.000 description 1
238000007906 compression Methods 0.000 description 1
230000006835 compression Effects 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
229930182912 cyclosporin Natural products 0.000 description 1
238000007922 dissolution test Methods 0.000 description 1
238000001035 drying Methods 0.000 description 1
238000005538 encapsulation Methods 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
150000002170 ethers Chemical class 0.000 description 1
150000002191 fatty alcohols Chemical class 0.000 description 1
230000030136 gastric emptying Effects 0.000 description 1
150000002314 glycerols Chemical class 0.000 description 1
239000008187 granular material Substances 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
239000002628 heparin derivative Substances 0.000 description 1
239000002634 heparin fragment Substances 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
229950003291 inogatran Drugs 0.000 description 1
229910010272 inorganic material Inorganic materials 0.000 description 1
239000011147 inorganic material Substances 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
239000007788 liquid Substances 0.000 description 1
238000004811 liquid chromatography Methods 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
239000002736 nonionic surfactant Substances 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
238000005191 phase separation Methods 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
239000011148 porous material Substances 0.000 description 1
238000012545 processing Methods 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
210000000813 small intestine Anatomy 0.000 description 1
239000003549 soybean oil Substances 0.000 description 1
235000012424 soybean oil Nutrition 0.000 description 1
239000012798 spherical particle Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
WBWWGRHZICKQGZ-HZAMXZRMSA-N taurocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@@H](O)C1 WBWWGRHZICKQGZ-HZAMXZRMSA-N 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
150000003626 triacylglycerols Chemical class 0.000 description 1
235000019155 vitamin A Nutrition 0.000 description 1
239000011719 vitamin A Substances 0.000 description 1
229940045997 vitamin a Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/005—Enzyme inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Epidemiology (AREA)
Inorganic Chemistry (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Hematology (AREA)
Diabetes (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

SK660-2000A 1997-11-28 1998-11-19 Porous hydroxyapatite particles as carriers for drug substances SK6602000A3 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
SE9704400A SE9704400D0 (sv)	1997-11-28	1997-11-28	Porous inorganic particles as carriers for drug substances
PCT/SE1998/002089 WO1999027912A1 (en)	1997-11-28	1998-11-19	Porous hydroxyapatite particles as carriers for drug substances

Publications (1)

Publication Number	Publication Date
SK6602000A3 true SK6602000A3 (en)	2001-01-18

Family

ID=20409177

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK660-2000A SK6602000A3 (en)	1997-11-28	1998-11-19	Porous hydroxyapatite particles as carriers for drug substances

Country Status (26)

Country	Link
US (1)	US6558703B1 (id)
EP (1)	EP1032370B1 (id)
JP (1)	JP2001524513A (id)
KR (1)	KR20010032557A (id)
CN (1)	CN1280492A (id)
AR (1)	AR016683A1 (id)
AT (1)	ATE256453T1 (id)
AU (1)	AU752044B2 (id)
BR (1)	BR9814751A (id)
CA (1)	CA2311780A1 (id)
DE (1)	DE69820674T2 (id)
DK (1)	DK1032370T3 (id)
ES (1)	ES2210840T3 (id)
HU (1)	HUP0100303A3 (id)
ID (1)	ID24700A (id)
IL (1)	IL136146A0 (id)
NO (1)	NO20002719L (id)
NZ (1)	NZ504353A (id)
PL (1)	PL340927A1 (id)
PT (1)	PT1032370E (id)
RU (1)	RU2219907C2 (id)
SE (1)	SE9704400D0 (id)
SK (1)	SK6602000A3 (id)
TW (1)	TW524694B (id)
WO (1)	WO1999027912A1 (id)
ZA (1)	ZA9810463B (id)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9924334D0 (en) *	1999-10-15	1999-12-15	Secr Defence	Pharmaceutical products and methods of fabrication therefor
DE60128683T2 (de) *	2000-04-11	2008-01-24	Sankyo Co., Ltd.	Stabilisierte pharmazeutische zusammenstellungen die den calziumkanalblocker azelnidipine enthalten
IT1319202B1 (it)	2000-10-12	2003-09-26	Nicox Sa	Farmaci per le malattie a base infiammatoria.
US6462021B1 (en)	2000-11-06	2002-10-08	Astrazeneca Ab	Use of low molecular weight thrombin inhibitor
EP1569912B1 (en)	2002-12-03	2015-04-29	Pharmacyclics, Inc.	2-(2-hydroxybiphenyl-3-yl)-1h-benzoimidazole-5-carboxamidine derivatives as factor viia inhibitors
KR101207553B1 (ko)	2005-06-02	2012-12-03	(주)씨앤팜	금속 이중층 수산화물을 포함하는 생체 주사제용 약물 담체
TW200806648A (en) *	2005-11-29	2008-02-01	Sankyo Co	Acid addition salts of dihydropyridine derivatives
TW200736245A (en) *	2005-11-29	2007-10-01	Sankyo Co	Acid addition salts of optically active dihydropyridine derivatives
JP5027410B2 (ja) *	2005-12-13	2012-09-19	株式会社サンギ	ユビキノン含有組成物
US8287914B2 (en) *	2006-01-12	2012-10-16	Rutgers, The State University Of New Jersey	Biomimetic hydroxyapatite synthesis
US20100040668A1 (en) *	2006-01-12	2010-02-18	Rutgers, The State University Of New Jersey	Biomimetic Hydroxyapatite Composite Materials and Methods for the Preparation Thereof
CA2644429C (en) *	2006-03-14	2014-07-29	Lidds Ab	Bioresorbable controlled-release composition
GB0909460D0 (en)	2009-06-02	2009-07-15	Intrinsiq Materials Global Ltd	Mesoporus material
PL2950923T3 (pl)	2013-02-01	2022-04-04	W.R. Grace & Co. - Conn.	Porowaty żel krzemionkowy jako nośnik płynnych technologii
CN105555259A (zh) *	2013-09-20	2016-05-04	蒂洛特斯制药股份有限公司	延迟释放的药物制剂
CN104133014B (zh) *	2014-07-16	2015-09-16	广州法尔麦兰药物技术有限公司	一种考察布洛伪麻缓释制剂释放度的方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8413191D0 (en)	1984-05-23	1984-06-27	Beecham Group Plc	Pharmaceutical composition
GB8713263D0 (en)	1987-06-05	1987-07-08	Unilever Plc	Spheroidal silica
EP0376331A3 (en)	1988-12-29	1991-03-13	Asahi Kogaku Kogyo Kabushiki Kaisha	Slow release drug delivery granules and process for production thereof
US5149523A (en) *	1989-06-20	1992-09-22	Aktiebolaget Hassle	Polystyrenesulfonate-drug complex and solid dosage forms thereof
DE4028906A1 (de) *	1990-09-12	1992-03-19	Paz Arzneimittelentwicklung	Arzneimittel sowie deren herstellung und deren verwendung bei der bekaempfung von schmerzen und/oder entzuendungen und/oder fieber an tieren und menschen
US5443459A (en) *	1991-01-30	1995-08-22	Alza Corporation	Osmotic device for delayed delivery of agent
US5834496A (en) *	1991-12-02	1998-11-10	Sepracor, Inc.	Methods for treating hypertension using optically pure S(-) felodipine
US5947893A (en) *	1994-04-27	1999-09-07	Board Of Regents, The University Of Texas System	Method of making a porous prothesis with biodegradable coatings
US6096324A (en) *	1995-06-13	2000-08-01	Laboratory Skin Care	Methods of delivering materials into the skin, and compositions used therein
JP3562878B2 (ja) *	1995-07-07	2004-09-08	丸尾カルシウム株式会社	花弁状多孔質ヒドロキシアパタイト微粒子及びその製造方法

1997
- 1997-11-28 SE SE9704400A patent/SE9704400D0/xx unknown
1998
- 1998-10-27 TW TW087117781A patent/TW524694B/zh not_active IP Right Cessation
- 1998-11-16 AR ARP980105798A patent/AR016683A1/es not_active Application Discontinuation
- 1998-11-16 ZA ZA9810463A patent/ZA9810463B/xx unknown
- 1998-11-18 US US09/214,318 patent/US6558703B1/en not_active Expired - Fee Related
- 1998-11-19 IL IL13614698A patent/IL136146A0/xx unknown
- 1998-11-19 PT PT98957268T patent/PT1032370E/pt unknown
- 1998-11-19 AT AT98957268T patent/ATE256453T1/de not_active IP Right Cessation
- 1998-11-19 EP EP98957268A patent/EP1032370B1/en not_active Expired - Lifetime
- 1998-11-19 WO PCT/SE1998/002089 patent/WO1999027912A1/en not_active Ceased
- 1998-11-19 NZ NZ504353A patent/NZ504353A/en unknown
- 1998-11-19 HU HU0100303A patent/HUP0100303A3/hu unknown
- 1998-11-19 ES ES98957268T patent/ES2210840T3/es not_active Expired - Lifetime
- 1998-11-19 CA CA002311780A patent/CA2311780A1/en not_active Abandoned
- 1998-11-19 PL PL98340927A patent/PL340927A1/xx unknown
- 1998-11-19 DK DK98957268T patent/DK1032370T3/da active
- 1998-11-19 DE DE69820674T patent/DE69820674T2/de not_active Expired - Lifetime
- 1998-11-19 CN CN98811634A patent/CN1280492A/zh active Pending
- 1998-11-19 RU RU2000113731/15A patent/RU2219907C2/ru not_active IP Right Cessation
- 1998-11-19 AU AU13563/99A patent/AU752044B2/en not_active Ceased
- 1998-11-19 KR KR1020007005802A patent/KR20010032557A/ko not_active Withdrawn
- 1998-11-19 SK SK660-2000A patent/SK6602000A3/sk unknown
- 1998-11-19 JP JP2000522898A patent/JP2001524513A/ja active Pending
- 1998-11-19 BR BR9814751-0A patent/BR9814751A/pt not_active IP Right Cessation
- 1998-11-19 ID IDW20000937A patent/ID24700A/id unknown
2000
- 2000-05-26 NO NO20002719A patent/NO20002719L/no unknown

Also Published As

Publication number	Publication date
HUP0100303A3 (en)	2004-03-29
ATE256453T1 (de)	2004-01-15
EP1032370A1 (en)	2000-09-06
PL340927A1 (en)	2001-03-12
NO20002719L (no)	2000-07-28
KR20010032557A (ko)	2001-04-25
ES2210840T3 (es)	2004-07-01
US6558703B1 (en)	2003-05-06
BR9814751A (pt)	2000-10-03
AU752044B2 (en)	2002-09-05
ID24700A (id)	2000-08-03
NZ504353A (en)	2001-10-26
IL136146A0 (en)	2001-05-20
NO20002719D0 (no)	2000-05-26
RU2219907C2 (ru)	2003-12-27
CA2311780A1 (en)	1999-06-10
PT1032370E (pt)	2004-05-31
JP2001524513A (ja)	2001-12-04
DK1032370T3 (da)	2004-03-15
AR016683A1 (es)	2001-07-25
SE9704400D0 (sv)	1997-11-28
AU1356399A (en)	1999-06-16
CN1280492A (zh)	2001-01-17
WO1999027912A1 (en)	1999-06-10
DE69820674D1 (de)	2004-01-29
TW524694B (en)	2003-03-21
EP1032370B1 (en)	2003-12-17
ZA9810463B (en)	1999-05-21
HUP0100303A2 (hu)	2001-08-28
DE69820674T2 (de)	2004-09-30

Publication	Publication Date	Title
SK6602000A3 (en)	2001-01-18	Porous hydroxyapatite particles as carriers for drug substances
US6555138B1 (en)	2003-04-29	Polyethylene glycol matrix pellets for greasy, oily or sticky drug substances
AU713192B2 (en)	1999-11-25	Tetrahydrolipstatin containing compositions
AU782282B2 (en)	2005-07-14	Pharmaceutical composition containing fenofibrate and preparation method
US6368622B2 (en)	2002-04-09	Process for preparing solid formulations of lipid regulating agents with enhanced dissolution and absorption
PL206595B1 (pl)	2010-08-31	Preparat farmaceutyczny w postaci mikrosfer, sposób wytwarzania tego preparatu oraz farmaceutyczna postać dawkowania zawierająca ten preparat
EP1032391B1 (en)	2002-05-15	Spheroids containing tiagabine, preparation process and pharmaceutical compositions
KR100380841B1 (ko)	2003-08-14	데소게스트렐(desogestrel)을함유하는정제또는캡슐
CZ20001946A3 (cs)	2000-10-11	Porézní částice hydroxyapatitu jako nosiče léčivých substancí
MXPA00005116A (en)	2002-03-05	Porous hydroxyapatite particles as carriers for drug substances
CZ20001945A3 (cs)	2000-10-11	Pelety z polyethylenglykolové matrice pro mastné, olejové nebo lepivé léčivé substance
CA2378987C (en)	2008-05-06	A binder for pharmaceutical compositions
MXPA00005112A (en)	2002-03-26	Polyethylene glycol matrix pellets for greasy, oily or sticky drug substances